UDC 619: 615.2.619: 618.19-002
DOI: 10.36871/vet.zoo.bio.202112003
Authors
Roman V. Rogov,
Yulia S. Kruglova,
Zhora Yu. Muradyan,
Moscow State Academy of Veterinary Medicine and Biotechnology – MVA by K. I. Skryabin”, Moscow, Russia
Abstract
The article presents the results of clinical trials of the veterinary drug «Mastinol-forte». The effectiveness
of the drug in the treatment of the serous-catarrhal form of mastitis was studied in
the conditions of a dairy farm. The experiment included cows of a black-and-white Holstein breed
weighing 500–550 kg, spontaneously ill with a clinical form of mastitis. Five groups of lactating
cows of 2–3 lactation were formed, with a yield of 7–8 thousand l/ year, 18 heads each. The therapeutic
efficacy of the drug was evaluated clinically by methods, as well as using a dimastin sample
and by counting somatic cells in milk samples.
It has been established that the use of the drug «Mastinol-forte» as monotherapy for serouscatarrhal
clinical mastitis in cows is well tolerated by animals and gives a positive effect both with
intramuscular, subcutaneous, and intracisternal injections. However, the best result was obtained
with the combined (subcutaneous and intracisternal) injection of mastinol-forte for 5 days at a dose
of 7 ml twice a day.
Keywords
serous-catarrhal mastitis, dimastin test, somatos-B, antimastitis drug, cows.
